OIG: HHS still not addressing copy-paste concerns

The Department of Health and Human Services (HHS) still has not adequately addressed the issue of hospitals failing to employ safeguards and prevent EHR fraud and abuse via recommended tools already in place, according to the Office of Inspector General (OIG). 

The OIG warned HHS about this shortcoming back in December 2013. The issue is listed in its annual compendium as one of  its top 25 unimplemented recommendations.

In its original report, OIG noted that HHS contracted with RTI International to develop recommendations to enhance data protection. Nearly all hospitals with EHRs had RTI-recommended audit functions in place, but that those functions were not being used to their full extent.

OIG's 2013 report also notes that too little was being done to limit the use of EHR copy-paste functions—24 percent of hospitals had policies regarding the use of such functions. "Although the copy-paste feature in EHRs can enhance efficiency of data entry, it may also facilitate attempts to inflate, duplicate or create fraudulent healthcare claims," the report reads.

Read the OIG's annual compendium.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.